Logo
D

Dewpoint Therapeutics

150 employees

Dewpoint Therapeutics is a biotech company developing a drug platform that targets biomolecular condensates.

Basic info

Industry

biotechnology research

Sectors

Biotechnology
Life Science
Health Care
insulin resistance
cardiopulmonary
virology
oncology
Therapeutics
Medical
biomolecular condensates
neurodegeneration
rare disease

Date founded

2018

Funding rounds raised

Total raised

$150M

from 18 investors over 18 rounds

D

Dewpoint Therapeutics raised $150M on February 3, 2022

Investors: Samsara BioCapital, NS Investment, Polaris Partners, Maverick Ventures, Leaps by Bayer, General Catalyst and SoftBank Investment Advisers

D

Dewpoint Therapeutics raised $77M on September 29, 2020

Investors: ARCH Venture Partners, Polaris Partners, Leaps by Bayer, Samsara BioCapital, Innovation Endeavors, Maverick Ventures and Bellco Capital

D

Dewpoint Therapeutics raised $60M on January 30, 2019

Investors: Leaps by Bayer, Samsara BioCapital, Polaris Partners and 6 Dimensions Capital

FAQ